Losing muscle can lead to a slower metabolism, poor posture, reduced strength, decreased bone density, and an increased risk of weight regain after stopping the medication
According to our 2026 Global GLP-1 Industry Statistics, the ability to stay on a single price point regardless of dose titration is one of the top three factors in long-term patient retention
Compared to DPP-4i users, GLP-1 RA users had statistically significant lower all-cause mortality, progression to cirrhosis, and cirrhosis-related complications.(6) Another retrospective cohort study in the United States included patients with type 2 diabetes and cirrhosis
Late-Breaking Clinical Trials II (Session 105) Saturday, March 28, 3:454:45 PM CT, Main Tent, Great Hall Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension
A free case review can help determine whether your experiences meet the criteria for participation in this developing litigation